Drug intelligence / Profile preview

cephalosporin + metronidazole

Development stage
Unknown
Lead developer
Hallym University Dongtan Sacred Heart Hospital
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Cephalosporin + metronidazole is an antibiotic combination regimen evaluated by Dongtan Sacred Heart Hospital for the treatment of acute uncomplicated right-sided diverticulitis. This combination therapy typically involves a third-generation cephalosporin, which provides broad-spectrum coverage against Gram-negative and Gram-positive aerobic bacteria by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Metronidazole is added to provide specific activity against anaerobic bacteria by disrupting DNA synthesis. In the clinical trial context (NCT02840110), the regimen was administered intravenously followed by an oral course to determine if antibiotic treatment is superior to supportive care (bowel rest) in patients with right-sided colonic diverticulitis.

Other names
3rd generation cephalosporin + metronidazolecephalosporin-Dongtan Sacred Heart Hospital-diverticulitis (right-sided)
02

Targets

THRB (Thyroid hormone receptor beta)PBP (Penicillin-binding protein family)Neuraminidase

Beyond the preview

Go deeper on cephalosporin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephalosporin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call